Spectrum of mutations in the gene for autosomal recessive polycystic kidney disease (ARPKD/PKHD1)

Carsten Bergmann, Jan Senderek, Beate Sedlacek, Ioannis Pegiazoglou, Patricia Puglia, Thomas Eggermann, Sabine Rudnik-Schöneborn, Laszlo Furu, Luiz F. Onuchic, Monica De Baca, Gregory G. Germino, Lisa Guay-Woodford, Stefan Somlo, Markus Moser, Reinhard Büttner, Klaus Zerres

Research output: Contribution to journalArticle

Abstract

Autosomal recessive polycystic kidney disease (ARPKD/PKHD1) is an important cause of renal-related and liver-related morbidity and mortality in childhood. Recently mutations in the PKHD1 gene on chromosome 6p21.1-p12 have been identified as the molecular cause of ARPKD. The longest continuous open reading frame (ORF) is encoded by a 67-exon transcript and predicted to yield a 4074-amino acid protein ("polyductin") of thus far unknown function. By now, a total of 29 different PKHD1 mutations have been described. This study reports mutation screening in 90 ARPKD patients and identifies mutations in 110 alleles making up a detection rate of 61%. Thirty-four of the detected mutations have not been reported previously. Two underlying mutations in 40 patients and one mutation in 30 cases are disclosed, and no mutation was detected on the remaining chromosomes. Mutations were found to be scattered throughout the gene without evidence of clustering at specific sites. About 45% of the changes were predicted to truncate the protein. All missense mutations were nonconservative, with the affected amino acid residues found to be conserved in the murine polyductin orthologue. One recurrent missense mutation (T36M) likely represents a mutational hotspot and occurs in a variety of populations. Two founder mutations (R496X and V3471G) make up about 60% of PKHD1 mutations in the Finnish population. Preliminary genotype-phenotype correlations could be established for the type of mutation rather than for the site of the individual mutation. All patients carrying two truncating mutations displayed a severe phenotype with perinatal or neonatal demise. PKHD1 mutation analysis is a powerful tool to establish the molecular cause of ARPKD in a given family. Direct identification of mutations allows an unequivocal diagnosis and accurate genetic counseling even in families displaying diagnostic challenges.

Original languageEnglish (US)
Pages (from-to)76-89
Number of pages14
JournalJournal of the American Society of Nephrology
Volume14
Issue number1
DOIs
StatePublished - Jan 1 2003

Fingerprint

Autosomal Recessive Polycystic Kidney
Mutation
Genes
Missense Mutation
Chromosomes
Amino Acids

ASJC Scopus subject areas

  • Nephrology

Cite this

Spectrum of mutations in the gene for autosomal recessive polycystic kidney disease (ARPKD/PKHD1). / Bergmann, Carsten; Senderek, Jan; Sedlacek, Beate; Pegiazoglou, Ioannis; Puglia, Patricia; Eggermann, Thomas; Rudnik-Schöneborn, Sabine; Furu, Laszlo; Onuchic, Luiz F.; De Baca, Monica; Germino, Gregory G.; Guay-Woodford, Lisa; Somlo, Stefan; Moser, Markus; Büttner, Reinhard; Zerres, Klaus.

In: Journal of the American Society of Nephrology, Vol. 14, No. 1, 01.01.2003, p. 76-89.

Research output: Contribution to journalArticle

Bergmann, C, Senderek, J, Sedlacek, B, Pegiazoglou, I, Puglia, P, Eggermann, T, Rudnik-Schöneborn, S, Furu, L, Onuchic, LF, De Baca, M, Germino, GG, Guay-Woodford, L, Somlo, S, Moser, M, Büttner, R & Zerres, K 2003, 'Spectrum of mutations in the gene for autosomal recessive polycystic kidney disease (ARPKD/PKHD1)', Journal of the American Society of Nephrology, vol. 14, no. 1, pp. 76-89. https://doi.org/10.1097/01.ASN.0000039578.55705.6E
Bergmann, Carsten ; Senderek, Jan ; Sedlacek, Beate ; Pegiazoglou, Ioannis ; Puglia, Patricia ; Eggermann, Thomas ; Rudnik-Schöneborn, Sabine ; Furu, Laszlo ; Onuchic, Luiz F. ; De Baca, Monica ; Germino, Gregory G. ; Guay-Woodford, Lisa ; Somlo, Stefan ; Moser, Markus ; Büttner, Reinhard ; Zerres, Klaus. / Spectrum of mutations in the gene for autosomal recessive polycystic kidney disease (ARPKD/PKHD1). In: Journal of the American Society of Nephrology. 2003 ; Vol. 14, No. 1. pp. 76-89.
@article{b8b6b1eb170a4a388d00e59f5c16b307,
title = "Spectrum of mutations in the gene for autosomal recessive polycystic kidney disease (ARPKD/PKHD1)",
abstract = "Autosomal recessive polycystic kidney disease (ARPKD/PKHD1) is an important cause of renal-related and liver-related morbidity and mortality in childhood. Recently mutations in the PKHD1 gene on chromosome 6p21.1-p12 have been identified as the molecular cause of ARPKD. The longest continuous open reading frame (ORF) is encoded by a 67-exon transcript and predicted to yield a 4074-amino acid protein ({"}polyductin{"}) of thus far unknown function. By now, a total of 29 different PKHD1 mutations have been described. This study reports mutation screening in 90 ARPKD patients and identifies mutations in 110 alleles making up a detection rate of 61{\%}. Thirty-four of the detected mutations have not been reported previously. Two underlying mutations in 40 patients and one mutation in 30 cases are disclosed, and no mutation was detected on the remaining chromosomes. Mutations were found to be scattered throughout the gene without evidence of clustering at specific sites. About 45{\%} of the changes were predicted to truncate the protein. All missense mutations were nonconservative, with the affected amino acid residues found to be conserved in the murine polyductin orthologue. One recurrent missense mutation (T36M) likely represents a mutational hotspot and occurs in a variety of populations. Two founder mutations (R496X and V3471G) make up about 60{\%} of PKHD1 mutations in the Finnish population. Preliminary genotype-phenotype correlations could be established for the type of mutation rather than for the site of the individual mutation. All patients carrying two truncating mutations displayed a severe phenotype with perinatal or neonatal demise. PKHD1 mutation analysis is a powerful tool to establish the molecular cause of ARPKD in a given family. Direct identification of mutations allows an unequivocal diagnosis and accurate genetic counseling even in families displaying diagnostic challenges.",
author = "Carsten Bergmann and Jan Senderek and Beate Sedlacek and Ioannis Pegiazoglou and Patricia Puglia and Thomas Eggermann and Sabine Rudnik-Sch{\"o}neborn and Laszlo Furu and Onuchic, {Luiz F.} and {De Baca}, Monica and Germino, {Gregory G.} and Lisa Guay-Woodford and Stefan Somlo and Markus Moser and Reinhard B{\"u}ttner and Klaus Zerres",
year = "2003",
month = "1",
day = "1",
doi = "10.1097/01.ASN.0000039578.55705.6E",
language = "English (US)",
volume = "14",
pages = "76--89",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "1",

}

TY - JOUR

T1 - Spectrum of mutations in the gene for autosomal recessive polycystic kidney disease (ARPKD/PKHD1)

AU - Bergmann, Carsten

AU - Senderek, Jan

AU - Sedlacek, Beate

AU - Pegiazoglou, Ioannis

AU - Puglia, Patricia

AU - Eggermann, Thomas

AU - Rudnik-Schöneborn, Sabine

AU - Furu, Laszlo

AU - Onuchic, Luiz F.

AU - De Baca, Monica

AU - Germino, Gregory G.

AU - Guay-Woodford, Lisa

AU - Somlo, Stefan

AU - Moser, Markus

AU - Büttner, Reinhard

AU - Zerres, Klaus

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Autosomal recessive polycystic kidney disease (ARPKD/PKHD1) is an important cause of renal-related and liver-related morbidity and mortality in childhood. Recently mutations in the PKHD1 gene on chromosome 6p21.1-p12 have been identified as the molecular cause of ARPKD. The longest continuous open reading frame (ORF) is encoded by a 67-exon transcript and predicted to yield a 4074-amino acid protein ("polyductin") of thus far unknown function. By now, a total of 29 different PKHD1 mutations have been described. This study reports mutation screening in 90 ARPKD patients and identifies mutations in 110 alleles making up a detection rate of 61%. Thirty-four of the detected mutations have not been reported previously. Two underlying mutations in 40 patients and one mutation in 30 cases are disclosed, and no mutation was detected on the remaining chromosomes. Mutations were found to be scattered throughout the gene without evidence of clustering at specific sites. About 45% of the changes were predicted to truncate the protein. All missense mutations were nonconservative, with the affected amino acid residues found to be conserved in the murine polyductin orthologue. One recurrent missense mutation (T36M) likely represents a mutational hotspot and occurs in a variety of populations. Two founder mutations (R496X and V3471G) make up about 60% of PKHD1 mutations in the Finnish population. Preliminary genotype-phenotype correlations could be established for the type of mutation rather than for the site of the individual mutation. All patients carrying two truncating mutations displayed a severe phenotype with perinatal or neonatal demise. PKHD1 mutation analysis is a powerful tool to establish the molecular cause of ARPKD in a given family. Direct identification of mutations allows an unequivocal diagnosis and accurate genetic counseling even in families displaying diagnostic challenges.

AB - Autosomal recessive polycystic kidney disease (ARPKD/PKHD1) is an important cause of renal-related and liver-related morbidity and mortality in childhood. Recently mutations in the PKHD1 gene on chromosome 6p21.1-p12 have been identified as the molecular cause of ARPKD. The longest continuous open reading frame (ORF) is encoded by a 67-exon transcript and predicted to yield a 4074-amino acid protein ("polyductin") of thus far unknown function. By now, a total of 29 different PKHD1 mutations have been described. This study reports mutation screening in 90 ARPKD patients and identifies mutations in 110 alleles making up a detection rate of 61%. Thirty-four of the detected mutations have not been reported previously. Two underlying mutations in 40 patients and one mutation in 30 cases are disclosed, and no mutation was detected on the remaining chromosomes. Mutations were found to be scattered throughout the gene without evidence of clustering at specific sites. About 45% of the changes were predicted to truncate the protein. All missense mutations were nonconservative, with the affected amino acid residues found to be conserved in the murine polyductin orthologue. One recurrent missense mutation (T36M) likely represents a mutational hotspot and occurs in a variety of populations. Two founder mutations (R496X and V3471G) make up about 60% of PKHD1 mutations in the Finnish population. Preliminary genotype-phenotype correlations could be established for the type of mutation rather than for the site of the individual mutation. All patients carrying two truncating mutations displayed a severe phenotype with perinatal or neonatal demise. PKHD1 mutation analysis is a powerful tool to establish the molecular cause of ARPKD in a given family. Direct identification of mutations allows an unequivocal diagnosis and accurate genetic counseling even in families displaying diagnostic challenges.

UR - http://www.scopus.com/inward/record.url?scp=12244300887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12244300887&partnerID=8YFLogxK

U2 - 10.1097/01.ASN.0000039578.55705.6E

DO - 10.1097/01.ASN.0000039578.55705.6E

M3 - Article

C2 - 12506140

AN - SCOPUS:12244300887

VL - 14

SP - 76

EP - 89

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 1

ER -